324 related articles for article (PubMed ID: 35750138)
21. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis.
Hou J; Zhang J; Cui P; Zhou Y; Liu C; Wu X; Ji Y; Wang S; Cheng B; Ye H; Shu L; Zhang K; Wang D; Xu J; Shu Q; Colonna M; Fang X
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586673
[TBL] [Abstract][Full Text] [Related]
22. Roles of Macrophages in Advanced Liver Fibrosis, Identified Using a Newly Established Mouse Model of Diet-Induced Non-Alcoholic Steatohepatitis.
Tada Y; Kasai K; Makiuchi N; Igarashi N; Kani K; Takano S; Honda H; Yanagibashi T; Watanabe Y; Usui-Kawanishi F; Furusawa Y; Ichimura-Shimizu M; Tabuchi Y; Takatsu K; Tsuneyama K; Nagai Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362037
[TBL] [Abstract][Full Text] [Related]
23. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
24. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.
Ye D; Yang K; Zang S; Lin Z; Chau HT; Wang Y; Zhang J; Shi J; Xu A; Lin S; Wang Y
J Hepatol; 2016 Nov; 65(5):988-997. PubMed ID: 27266617
[TBL] [Abstract][Full Text] [Related]
25. The immunoregulatory effects of CD8 T-cell-derived perforin on diet-induced nonalcoholic steatohepatitis.
Wang T; Sun G; Wang Y; Li S; Zhao X; Zhang C; Jin H; Tian D; Liu K; Shi W; Tian Y; Zhang D
FASEB J; 2019 Jul; 33(7):8490-8503. PubMed ID: 30951375
[TBL] [Abstract][Full Text] [Related]
26. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
27. TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization.
Luo Y; Guo J; Jia W; Wu M; Yin F; Niu G; Shih DQ; Targan SR; Zhang X
Oxid Med Cell Longev; 2021; 2021():3877617. PubMed ID: 35003513
[TBL] [Abstract][Full Text] [Related]
28. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
[TBL] [Abstract][Full Text] [Related]
29. Integrin β
Guo Q; Furuta K; Lucien F; Gutierrez Sanchez LH; Hirsova P; Krishnan A; Kabashima A; Pavelko KD; Madden B; Alhuwaish H; Gao Y; Revzin A; Ibrahim SH
J Hepatol; 2019 Dec; 71(6):1193-1205. PubMed ID: 31433301
[TBL] [Abstract][Full Text] [Related]
30. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
31. Human amnion epithelial cells and their soluble factors reduce liver fibrosis in murine non-alcoholic steatohepatitis.
Kuk N; Hodge A; Sun Y; Correia J; Alhomrani M; Samuel C; Moore G; Lim R; Sievert W
J Gastroenterol Hepatol; 2019 Aug; 34(8):1441-1449. PubMed ID: 30821873
[TBL] [Abstract][Full Text] [Related]
32. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages.
McGettigan B; McMahan R; Orlicky D; Burchill M; Danhorn T; Francis P; Cheng LL; Golden-Mason L; Jakubzick CV; Rosen HR
Hepatology; 2019 Jul; 70(1):67-83. PubMed ID: 30516830
[TBL] [Abstract][Full Text] [Related]
33. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis.
Hammoutene A; Biquard L; Lasselin J; Kheloufi M; Tanguy M; Vion AC; Mérian J; Colnot N; Loyer X; Tedgui A; Codogno P; Lotersztajn S; Paradis V; Boulanger CM; Rautou PE
J Hepatol; 2020 Mar; 72(3):528-538. PubMed ID: 31726115
[TBL] [Abstract][Full Text] [Related]
34. Egr2 drives the differentiation of Ly6C
Iwata A; Maruyama J; Natsuki S; Nishiyama A; Tamura T; Tanaka M; Shichino S; Seki T; Komai T; Okamura T; Fujio K; Tanaka M; Asano K
Commun Biol; 2024 Jun; 7(1):681. PubMed ID: 38831027
[TBL] [Abstract][Full Text] [Related]
35. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
36. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
Fraser DA; Wang X; Lund J; Nikolić N; Iruarrizaga-Lejarreta M; Skjaeret T; Alonso C; Kastelein JJP; Rustan AC; Kim YO; Schuppan D
J Hepatol; 2022 Apr; 76(4):800-811. PubMed ID: 34915054
[TBL] [Abstract][Full Text] [Related]
37. TREM2 Insufficiency Protects against Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization.
Luo Q; Deng D; Li Y; Shi H; Zhao J; Qian Q; Wang W; Cai J; Yu W; Liu J
Int Immunopharmacol; 2023 May; 118():110070. PubMed ID: 37003186
[TBL] [Abstract][Full Text] [Related]
38. Brain-derived neurotrophic factor knock-out mice develop non-alcoholic steatohepatitis.
Ichimura-Shimizu M; Kojima M; Suzuki S; Miyata M; Osaki Y; Matsui K; Mizui T; Tsuneyama K
J Pathol; 2023 Dec; 261(4):465-476. PubMed ID: 37781961
[TBL] [Abstract][Full Text] [Related]
39. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
[TBL] [Abstract][Full Text] [Related]
40. SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease.
Novo E; Cappon A; Villano G; Quarta S; Cannito S; Bocca C; Turato C; Guido M; Maggiora M; Protopapa F; Sutti S; Provera A; Ruvoletto M; Biasiolo A; Foglia B; Albano E; Pontisso P; Parola M
Front Immunol; 2022; 13():910526. PubMed ID: 35874657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
